Answer
In LITESPARK-005 patients with advanced renal cell carcinoma, the most common adverse reactions to belzutifan were anaemia (83%), fatigue (31%), nausea (18%), dyspnoea (15%), hypoxia (15%) and dizziness (12%).
Sources for this answer
- WELIREG 40 mg film-coated tabletsMerck Sharp & Dohme (UK) Limited · emc · SmPC §4.8 Undesirable effects · Version 9Document updated
Sources checked